Drugs / Recombinant SeV-hFGF2/dF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03668353 | Sep 2018 → Mar 2020 | limb ischemia, peripheral arterial disease, peripheral arterial occlusive disease 1 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant SeV-hFGF2/dF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03668353 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT03668353 ↗ |
| Target | FGF2 | “uses the human basic fibroblast growth factor ( FGF2 ) gene to express the target protein FGF2 locally” NCT03668353 ↗ |